Non-Steroidal Anti-Inflammatory Drugs Increase the Antiretroviral Activity of Nucleoside Reverse Transcriptase Inhibitors in HIV Type-1-Infected T-Lymphocytes: Role of Multidrug Resistance Protein 4
Free accessResearch articleFirst published online November, 2009
Non-Steroidal Anti-Inflammatory Drugs Increase the Antiretroviral Activity of Nucleoside Reverse Transcriptase Inhibitors in HIV Type-1-Infected T-Lymphocytes: Role of Multidrug Resistance Protein 4
The multidrug resistance proteins (MRPs) form a subfamily within the ATP binding cassette transporters that confer resistance to a variety of structurally unrelated compounds. MRP4 has been reported to transport antiretroviral drugs out of cells in an active process. Although the main therapeutic effects of non-steroidal anti-inflammatory drugs (NSAIDs) are their ability to inhibit cyclooxygenase activity, in recent years, some pharmacological effects independent of this action have been described, such as inhibition of the activity of MRP4.
Methods
Detection of MRP4 expression was carried out by Western blot analysis, immunofluorescence and flow cytometry in peripheral blood lymphocytes (PBLs). Cells were infected with HIV type-1NL4.3 isolate, and treated with anti-retroviral drugs plus different NSAIDs. Agp24 was measured by ELISA 3 days post-infection. Intracellular [3H] zidovudine (AZT) was quantified by a scintiller counter. Expression of different cell markers was assessed by flow cytometry.
Results
NSAIDs, as well as probenecid, were able to potentiate the antiretroviral effect of several nucleoside reverse transcriptase inhibitors (NRTIs). PBLs expressed MRP4 and treatment with ibuprofen did not affect this expression. However, MRP4 expression increased following phytohaemaglutinin and AZT treatment. This decrease of Agp24 was correlated with an increase in the intracellular AZT concentration. This effect was unrelated to changes on expression of CD4, CXCR4, cell viability or activation. Interestingly, patients treated with highly active antiretroviral therapy, who had a detectable viral load, presented a higher expression of MRP4 than those with an undetectable viral load.
Conclusions
NSAIDs can improve the antiretroviral activity of NRTIs, increasing their intracellular concentration by blocking MRP4. This finding could have implications for success of antiviral therapy.
References
1.
DurantJ., ClevenberghP., HalfonP.Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial.Lancet1999; 353: 2195–2199.
2.
GroschelB., CinatlJ., CinatlJ.Jr., Viral and cellular factors for resistance against antiretroviral agents.Intervirology1997; 40: 400–407.
3.
HoggardP.G., OwenA.The mechanisms that control intracellular penetration of the HIV protease inhibitors.J Antimicrob Chemother2003; 51: 493–496.
4.
SchuetzJ.D., ConnellyM.C., SunD.MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs.Nat Med1999; 5: 1048–1051.
5.
BorstP., ElferinkR.O.Mammalian ABC transporters in health and disease.Annu Rev Biochem2002; 71: 537–592.
6.
RusselF.G., KoenderinkJ.B., MasereeuwR.Multidrug resistance protein 4 (MRP4/ABCC4): a versatile efflux transporter for drugs and signalling molecules.Trends Pharmacol Sci2008; 29: 200–207.
7.
LeslieE.M., DeeleyR.G., ColeS.P.Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters.Toxicology2001; 167: 3–23.
8.
KonigJ., NiesA.T., CuiY., LeierI., KepplerD.Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance.Biochim Biophys Acta1999; 1461: 377–394.
9.
HaimeurA., ConseilG., DeeleyR.G., ColeS.P.The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation.Curr Drug Metab2004; 5: 21–53.
10.
DallasS., MillerD.S., BendayanR.Multidrug resistance-associated proteins: expression and function in the central nervous system.Pharmacol Rev2006; 58: 140–161.
11.
BorstP., de WolfC., van de WeteringK.Multidrug resistance-associated proteins 3, 4, and 5.Pflugers Arch2007; 453: 661–673.
12.
GuoY., KotovaE., ChenZ.S.MRP8, ATP-binding cassette C11 (ABCC11), is a cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidines 2’,3’-dideoxycytidine and 9’-(2’-phosphonylmethoxyethyl) adenine.J Biol Chem2003; 278: 29509–29514.
13.
KruhG.D., BelinskyM.G.The MRP family of drug efflux pumps.Oncogene2003; 22: 7537–7552.
14.
SrinivasR.V., MiddlemasD., FlynnP., FridlandA.Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters.Antimicrob Agents Chemother1998; 42: 3157–3162.
15.
JonesK., BrayP.G., KhooS.H.P-Glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance?AIDS2001; 15: 1353–1358.
16.
JannehO., OwenA., ChandlerB.Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP.AIDS2005; 19: 2097–2102.
17.
ReidG., WielingaP., ZelcerN.Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5.Mol Pharmacol2003; 63: 1094–1103.
18.
WijnholdsJ., MolC.A., van DeemterL.Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs.Proc Natl Acad Sci U S A2000; 97: 7476–7481.
19.
DallasS., SchlichterL., BendayanR.Multidrug resistance protein (MRP) 4- and MRP 5-mediated efflux of 9-(2-phosphonylmethoxyethyl)adenine by microglia.J Pharmacol Exp Ther2004; 309: 1221–1229.
20.
ImaokaT., KusuharaH., AdachiM.Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir.Mol Pharmacol2007; 71: 619–627.
HanS., InoueH., FlowersL.C., SidellN.Control of COX-2 gene expression through peroxisome proliferator-activated receptor gamma in human cervical cancer cells.Clin Cancer Res2003; 9: 4627–4635.
23.
StichtenothD.O., WagnerB., FrolichJ.C.Effects of meloxicam and indomethacin on cyclooxygenase pathways in healthy volunteers.J Investig Med1997; 45: 44–49.
24.
TegederI., PfeilschifterJ., GeisslingerG.Cyclooxygenase-independent actions of cyclooxygenase inhibitors.FASEB J2001; 15: 2057–2072.
25.
ReidG., WielingaP., ZelcerN.The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs.Proc Natl Acad Sci U S A2003; 100: 9244–9249.
26.
TurrizianiO., PagnottiP., PierangeliA.The effects of prolonged treatment with zidovudine, lamivudine, and abacavir on a T-lymphoblastoid cell line.AIDS Res Hum Retroviruses2006; 22: 960–967.
27.
TurrizianiO., SchuetzJ.D., FocherF.Impaired 2’,3’-dideoxy-3’-thiacytidine accumulation in T-lymphoblastoid cells as a mechanism of acquired resistance independent of multidrug resistant protein 4 with a possible role for ATP-binding cassette C11.Biochem J2002; 368: 325–332.
28.
WarnerT.D., MitchellJ.A.Nonsteroidal antiinflammatory drugs inhibiting prostanoid efflux: as easy as ABC?Proc Natl Acad Sci U S A2003; 100: 9108–9110.
29.
CourtoisA., PayenL., LagadicD., GuillouzoA., FardelO.Evidence for a multidrug resistance-associated protein 1 (MRP1)-related transport system in cultured rat liver biliary epithelial cells.Life Sci1999; 64: 763–774.
30.
PayenL., CourtoisA., VernhetL., GuillouzoA., FardelO.The multidrug resistance-associated protein (MRP) is over-expressed and functional in rat hepatoma cells.Int J Cancer1999; 81: 479–485.
31.
TurrizianiO., GianottiN., FalascaF.Expression levels of MDR1, MRP1, MRP4, and MRP5 in peripheral blood mononuclear cells from HIV infected patients failing antiretroviral therapy.J Med Virol2008; 80: 766–771.
32.
IniguezM.A., PunzonC., FresnoM.Induction of cyclooxygenase-2 on activated T lymphocytes: regulation of T cell activation by cyclooxygenase-2 inhibitors.J Immunol1999; 163: 111–119.
33.
SwanstromR., EronaJ.Human immunodeficiency virus type-1 protease inhibitors: therapeutic successes and failures, suppression and resistance.Pharmacol Ther2000; 86: 145–170.
34.
DeeleyR.G., WestlakeC., ColeS.P.Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins.Physiol Rev2006; 86: 849–899.
35.
ChenZ.S., LeeK., KruhG.D.Transport of cyclic nucleotides and estradiol 17-beta-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine.J Biol Chem2001; 276: 33747–33754.
36.
van AubelR.A., SmeetsP.H., PetersJ.G., BindelsR.J., RusselF.G.The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP.J Am Soc Nephrol2002; 13: 595–603.
37.
WielingaP.R., van der HeijdenI., ReidG.Characterization of the MRP4- and MRP5-mediated transport of cyclic nucleotides from intact cells.J Biol Chem2003; 278: 17664–17671.
38.
JedlitschkyG., TirschmannK., LubenowL.E.The nucleotide transporter MRP4 (ABCC4) is highly expressed in human platelets and present in dense granules, indicating a role in mediator storage.Blood2004; 104: 3603–3610.
39.
El-SheikhA.A., van den HeuvelJ.J., KoenderinkJ.B., RusselF.G.Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport.J Pharmacol Exp Ther2007; 320: 229–235.
40.
SassiY., LipskaiaL., VandecasteeleG.Multidrug resistance-associated protein 4 regulates cAMP-dependent signaling pathways and controls human and rat SMC proliferation.J Clin Invest2008; 118: 2747–2757.
41.
NorrisM.D., SmithJ., TanabeK.Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro.Mol Cancer Ther2005; 4: 547–553.
42.
ChandlerB., AlmondL., FordJ.The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro.J Acquir Immune Defic Syndr2003; 33: 551–556.
43.
MaherJ.M., DieterM.Z., AleksunesL.M.Oxidative and electrophilic stress induces multidrug resistance-associated protein transporters via the nuclear factor-E2-related factor-2 transcriptional pathway.Hepatology2007; 46: 1597–1610.
44.
GradiloneA., PulcinelliF.M., LottiL.V.Celecoxib induces MRP-4 in lung cancer cells: therapeutic implications.J Clin Oncol2007; 25: 4318–4320, author reply 4320.
45.
JorajuriaS., Dereuddre-BosquetN., BecherF.ATP binding cassette multidrug transporters limit the anti-HIV activity of zidovudine and indinavir in infected human macrophages.Antivir Ther2004; 9: 519–528.
46.
TakadaY., BhardwajA., PotdarP., AggarwalB.B.Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation.Oncogene2004; 23: 9247–9258.
47.
JorajuriaS., Dereuddre-BosquetN., Naissant-StorckK., DormontD., ClayetteP.Differential expression levels of MRP1, MRP4, and MRP5 in response to human immunodeficiency virus infection in human macrophages.Antimicrob Agents Chemother2004; 48: 1889–1891.
